E H Estey

Summary

Affiliation: The University of Texas
Country: USA

Publications

  1. ncbi Prospective feasibility analysis of reduced-intensity conditioning (RIC) regimens for hematopoietic stem cell transplantation (HSCT) in elderly patients with acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS)
    Elihu Estey
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston 77030, USA
    Blood 109:1395-400. 2007
  2. ncbi Therapeutic research in untreated acute promyelocytic leukemia
    E Estey
    Leukemia Department, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Leukemia 19:913-5. 2005
  3. ncbi Treatment options for relapsed acute promyelocytic leukaemia
    Elihu H Estey
    Chief Section of AML MDS, Department of Leukemia, M D Anderson Cancer Center, University of Texas, 1515 Holcombe Blvd, Box 428, Houston, TX 77030, USA
    Best Pract Res Clin Haematol 16:521-34. 2003
  4. ncbi Therapeutic options for acute myelogenous leukemia
    E H Estey
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030 4095, USA
    Cancer 92:1059-73. 2001
  5. ncbi Current challenges in therapy of myelodysplastic syndromes
    Elihu H Estey
    Department of Leukemia, University of Texas, M D Anderson Cancer Center, Houston 77030, USA
    Curr Opin Hematol 10:60-7. 2003
  6. ncbi Acute myeloid leukaemia
    Elihu Estey
    Leukemia Department, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Lancet 368:1894-907. 2006
  7. ncbi Use of all-trans retinoic acid plus arsenic trioxide as an alternative to chemotherapy in untreated acute promyelocytic leukemia
    Elihu Estey
    Department of Leukemia, University of Texas M D Anderson Cancer Center, 1515 Holcombe, Box 428, Houston, 77030, USA
    Blood 107:3469-73. 2006
  8. ncbi General approach to, and perspectives on clinical research in, older patients with newly diagnosed acute myeloid leukemia
    Elihu H Estey
    Department of Leukemia, M D Anderson Cancer Center, Houston, TX 77030, USA
    Semin Hematol 43:89-95. 2006
  9. ncbi New designs for phase 2 clinical trials
    Elihu H Estey
    Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, USA
    Blood 102:442-8. 2003
  10. ncbi Experience with gemtuzumab ozogamycin ("mylotarg") and all-trans retinoic acid in untreated acute promyelocytic leukemia
    Elihu H Estey
    Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston 77030, USA
    Blood 99:4222-4. 2002

Collaborators

Detail Information

Publications104 found, 100 shown here

  1. ncbi Prospective feasibility analysis of reduced-intensity conditioning (RIC) regimens for hematopoietic stem cell transplantation (HSCT) in elderly patients with acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS)
    Elihu Estey
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston 77030, USA
    Blood 109:1395-400. 2007
    ..99 (P=.004). Results were similar with respect to survival. While RIC-HSCT thus seems of interest, methods are needed to extend its applicability...
  2. ncbi Therapeutic research in untreated acute promyelocytic leukemia
    E Estey
    Leukemia Department, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Leukemia 19:913-5. 2005
  3. ncbi Treatment options for relapsed acute promyelocytic leukaemia
    Elihu H Estey
    Chief Section of AML MDS, Department of Leukemia, M D Anderson Cancer Center, University of Texas, 1515 Holcombe Blvd, Box 428, Houston, TX 77030, USA
    Best Pract Res Clin Haematol 16:521-34. 2003
    ..We note the significance of extramedullary relapse. We conclude with a summary of treatment recommendations and a discussion of new therapies that might be useful in the future...
  4. ncbi Therapeutic options for acute myelogenous leukemia
    E H Estey
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030 4095, USA
    Cancer 92:1059-73. 2001
    ..General therapeutic options for patients with acute myelogenous leukemia (AML) are reviewed and specific new therapies are described...
  5. ncbi Current challenges in therapy of myelodysplastic syndromes
    Elihu H Estey
    Department of Leukemia, University of Texas, M D Anderson Cancer Center, Houston 77030, USA
    Curr Opin Hematol 10:60-7. 2003
    ....
  6. ncbi Acute myeloid leukaemia
    Elihu Estey
    Leukemia Department, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Lancet 368:1894-907. 2006
    ..Current efforts in clinical research focus on the assessment of targeted therapies. Such new approaches will probably lead to an increase in the cure rate...
  7. ncbi Use of all-trans retinoic acid plus arsenic trioxide as an alternative to chemotherapy in untreated acute promyelocytic leukemia
    Elihu Estey
    Department of Leukemia, University of Texas M D Anderson Cancer Center, 1515 Holcombe, Box 428, Houston, 77030, USA
    Blood 107:3469-73. 2006
    ..ATRA plus ATO may serve as an alternative to chemotherapy in low-risk untreated APL (eg, in older patients) and, when combined with GO, may improve outcome in high-risk patients...
  8. ncbi General approach to, and perspectives on clinical research in, older patients with newly diagnosed acute myeloid leukemia
    Elihu H Estey
    Department of Leukemia, M D Anderson Cancer Center, Houston, TX 77030, USA
    Semin Hematol 43:89-95. 2006
    ....
  9. ncbi New designs for phase 2 clinical trials
    Elihu H Estey
    Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, USA
    Blood 102:442-8. 2003
    ..These concerns motivated the development of a general paradigm for randomized selection trials evaluating several therapies based on multiple outcomes. Three illustrative applications of trials using this approach are presented...
  10. ncbi Experience with gemtuzumab ozogamycin ("mylotarg") and all-trans retinoic acid in untreated acute promyelocytic leukemia
    Elihu H Estey
    Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston 77030, USA
    Blood 99:4222-4. 2002
    ..A median of 5 post-CR courses have been given to date with 3 patients having currently received 8 post-CR courses, and 4 patients receiving 7 post-CR courses. Mylotarg appears active in APL, and repeated administration is feasible...
  11. ncbi Acute myeloid leukemia and myelodysplastic syndromes in older patients
    Elihu Estey
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    J Clin Oncol 25:1908-15. 2007
    ..Lenalidomide, azacitidine, and decitabine, each recently approved by the US Food and Drug Administration, are useful in achieving these objectives...
  12. ncbi Effect of circulating blasts at time of complete remission on subsequent relapse-free survival time in newly diagnosed AML
    Elihu H Estey
    Department of Leukemia, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Box 428, Houston, TX 77030, USA
    Blood 102:3097-9. 2003
    ..0. Thus, our data do not support use of PBBs in defining CR in newly diagnosed AML...
  13. ncbi Clinical trials in AML of the elderly: should we change our methodology?
    E Estey
    Department of Leukemia, University of Texas MD Anderson Cancer Center, Holcombe, Houston, TX, USA
    Leukemia 18:1772-4. 2004
  14. ncbi Randomized phase II study of fludarabine + cytosine arabinoside + idarubicin +/- all-trans retinoic acid +/- granulocyte colony-stimulating factor in poor prognosis newly diagnosed acute myeloid leukemia and myelodysplastic syndrome
    E H Estey
    Department of Leukemia, Division of Medicine, The University of Texas M D Anderson Cancer Center, Houston, TX, USA
    Blood 93:2478-84. 1999
    ..We conclude that addition of ATRA +/- G-CSF to FAI had no effect on CR rate, survival, EFS, or EFS in CR in poor prognosis, newly diagnosed AML or high-risk MDS...
  15. ncbi Molecular remissions induced by liposomal-encapsulated all-trans retinoic acid in newly diagnosed acute promyelocytic leukemia
    E H Estey
    Department of Leukemia Therapy, The University of Texas M D Anderson Cancer Center, Houston, TX, USA
    Blood 94:2230-5. 1999
    ..Our data suggest that lipoATRA is an effective means of producing molecular CR in newly diagnosed APL...
  16. ncbi Comparison of idarubicin + ara-C-, fludarabine + ara-C-, and topotecan + ara-C-based regimens in treatment of newly diagnosed acute myeloid leukemia, refractory anemia with excess blasts in transformation, or refractory anemia with excess blasts
    E H Estey
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Blood 98:3575-83. 2001
    ..It is unlikely that, as given here, either FA or TA is, in general, superior to IA, highlighting the need for new treatments...
  17. ncbi Having a higher blast percentage in circulation than bone marrow: clinical implications in myelodysplastic syndrome and acute lymphoid and myeloid leukemias
    H M Amin
    Department of Hematopathology, University of Texas MD Anderson Cancer Center, Houston, TX, USA
    Leukemia 19:1567-72. 2005
    ..These data also suggest that MDS classification schemes should take into account the percentage of blasts in PB differently from the percentage of blasts in BM...
  18. ncbi Effect of time to complete remission on subsequent survival and disease-free survival time in AML, RAEB-t, and RAEB
    E H Estey
    Department of Leukemia, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Blood 95:72-7. 2000
    ..Time to CR is an independent predictor of residual survival and disease-free survival in patients with newly diagnosed AML who achieve CR after 1 course of chemotherapy. (Blood. 2000;95:72-77)..
  19. ncbi Mylotarg (gemtuzumab ozogamicin) therapy is associated with hepatic venoocclusive disease in patients who have not received stem cell transplantation
    F J Giles
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030 4095, USA
    Cancer 92:406-13. 2001
    ..Hepatic venoocclusive disease (VOD) has been reported in patients who have undergone stem cell transplantation (SCT) after Mylotarg therapy. Outside of the SCT setting, VOD has been associated very rarely with cytotoxic therapy...
  20. ncbi Thiotepa, busulfan, and cyclophosphamide as a preparative regimen for allogeneic transplantation for advanced myelodysplastic syndrome and acute myelogenous leukemia
    S Bibawi
    Department of Blood and Marrow Transplantation, The University of Texas M.D. Anderson Cancer Center, Houston, Texas 77030, USA
    Am J Hematol 67:227-33. 2001
    ..TBC is an active preparative regimen for advanced AML. Patients with advanced MDS appeared to have a higher risk of toxicity and early mortality, and alternative preparative regimens should be considered for these patients...
  21. ncbi Identification of a group of AML/MDS patients with a relatively favorable prognosis who have chromosome 5 and/or 7 abnormalities
    E H Estey
    Department of Leukemia, Box 61, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Houston, Texas 77030, USA
    Haematologica 85:246-9. 2000
    ..Our objective was to see whether the occasional relatively favorable outcome in -5/-7 patients is a random event or, rather, reflects true heterogeneity in -5/-7...
  22. ncbi High-dose chemotherapy in high-risk myelodysplastic syndrome: covariate-adjusted comparison of five regimens
    M Beran
    Department of Leukemia, University of Texas, M D Anderson Cancer Center, Houston, Texas 77030 4095, USA
    Cancer 92:1999-2015. 2001
    ..Because the results of standard regimens have been disappointing, high-dose chemotherapeutic regimens were investigated recently. In the absence of randomized trials, the relative merits of various treatment regimens are unknown...
  23. ncbi Treatment of newly-diagnosed acute promyelocytic leukemia with liposomal all-trans retinoic acid
    E Estey
    Department of Leukemia, University of Texas, M D Anderson Cancer Center, Houston, TX 77030, USA
    Leuk Lymphoma 42:309-16. 2001
    ..Nonetheless, the rates and duration of PCR negativity produced by lipoATRA monotherapy suggest that lipoATRA is a superior anti-APL agent than oral ATRA...
  24. ncbi Minimum dose of fludarabine for the maximal modulation of 1-beta-D-arabinofuranosylcytosine triphosphate in human leukemia blasts during therapy
    V Gandhi
    Departments of Clinical Investigation and Hematology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Cancer Res 3:1539-45. 1997
    ..These findings point to the feasibility of intensifying the fludarabine-ara-C regimen by using fludarabine as a 15 mg/m2/dose twice daily with intermediate-dose ara-C...
  25. ncbi Better detection of FLT3 internal tandem duplication using peripheral blood plasma DNA
    I Jilani
    Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Leukemia 17:114-9. 2003
    ..Furthermore, the data derived from this study support the notion that the presence of FLT3 ITD in conjunction with the absence of the wild-type FLT3 allele predicts an especially poor prognosis for patients with AML...
  26. ncbi Cellular ara-CTP pharmacokinetics, response, and karyotype in newly diagnosed acute myelogenous leukemia
    E H Estey
    Department of Hematology, University of Texas M D Anderson Cancer Center, Houston 77030
    Leukemia 4:95-9. 1990
    ....
  27. ncbi Accrual strategies for phase I trials with delayed patient outcome
    P F Thall
    Department of Biomathematics, University of Texas M D Anderson Cancer Center, Houston 77030, USA
    Stat Med 18:1155-69. 1999
    ..Based on our results, we provide practical guidelines for deciding among these approaches and strategies in a given clinical setting...
  28. ncbi Soluble phosphorylated fms-like tyrosine kinase III. FLT3 protein in patients with acute myeloid leukemia (AML)
    F Ravandi
    Leukemia Department, The University of Texas, M D Anderson Cancer Center, Houston, Texas 77030, USA
    Leuk Res 31:791-7. 2007
    ..04). Other mechanisms may be responsible for abnormal phosphorylation of FLT3 and inhibitors of FLT3 should also be investigated in patients without mutations...
  29. ncbi A prognostic score for patients with lower risk myelodysplastic syndrome
    G Garcia-Manero
    Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Leukemia 22:538-43. 2008
    ..2 months (95% CI 13-18). In summary, this analysis indicates that it is possible to identify patients with lower risk MDS and poor prognosis who may benefit from early intervention...
  30. ncbi Leukapheresis reduces early mortality in patients with acute myeloid leukemia with high white cell counts but does not improve long- term survival
    F J Giles
    Departments of Leukemia, Biostatistics, and Blood and Marrow Transplantation, University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Box 61, Houston, TX 77030, USA
    Leuk Lymphoma 42:67-73. 2001
    ....
  31. ncbi Phase I study of irofulven (MGI 114), an acylfulvene illudin analog, in patients with acute leukemia
    F Giles
    Department of Leukemia, The University of Texas M D Anderson Cancer Center Houston, Texas 77030 4095, USA
    Invest New Drugs 19:13-20. 2001
    ....
  32. ncbi Significance of angiogenin plasma concentrations in patients with acute myeloid leukaemia and advanced myelodysplastic syndrome
    S Verstovsek
    Department of Leukemia, The University of Texas, M. D. Anderson Cancer Center, Houston, TX 77030, USA
    Br J Haematol 114:290-5. 2001
    ..In multivariate analysis, angiogenin concentration retained its significance as a prognostic factor in AML (P = 0.03), together with age (P = 0.00007) and haemoglobin (P = 0.03)...
  33. ncbi High-dose liposomal daunorubicin and high-dose cytarabine combination in patients with refractory or relapsed acute myelogenous leukemia
    J Cortes
    Department of Leukemia, University of Texas, M D Anderson Cancer Center, Houston, Texas, USA
    Cancer 92:7-14. 2001
    ....
  34. ncbi Outcome in patients with nonleukemic granulocytic sarcoma treated with chemotherapy with or without radiotherapy
    A M Tsimberidou
    Department of Leukemia, The University of Texas, MD Anderson Cancer Center, 1400 Holcombe Boulevard, Houston, TX 77030, USA
    Leukemia 17:1100-3. 2003
    ..The median survival of patients with chromosome 8 abnormalities was 12 months compared with 40 months of those without (P=0.17). Novel therapies for patients with GS are required...
  35. ncbi Disease burden may identify patients more likely to benefit from second allogeneic hematopoietic stem cell transplantation to treat relapsed acute myelogenous leukemia
    C Hosing
    Department of Blood and Marrow Transplantation, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Bone Marrow Transplant 36:157-62. 2005
    ..Thus, a second transplant may offer the possibility of long-term disease control in a subset of patients who have a 'low bulk' disease at the time of transplantation...
  36. ncbi Antithymocyte globulin (ATG)-based therapy in patients with myelodysplastic syndromes
    S Yazji
    Department of Leukemia, University of Texas, MD Anderson Cancer Center, Houston, TX 77030, USA
    Leukemia 17:2101-6. 2003
    ..Hepatic and renal dysfunction, albeit consistently reversible, occurred in 19 and 13% of the patients, respectively. In conclusion, an ATG-based regimen can produce durable complete remissions in a subset of patients with MDS...
  37. ncbi New designs for phase II trials: application to a trial of targeted therapies vs. chemotherapy in patients age > 60 with AML/high-risk MDS
    E H Estey
    Dept Leukemia, Box 428, U T M D Anderson Cancer Center, 1515 Holcombe, Houston, Tex 77030, USA
    Ann Hematol 83:S94-6. 2004
  38. ncbi Growth factors in acute myeloid leukaemia
    E H Estey
    Department of Leukemia, The University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
    Best Pract Res Clin Haematol 14:175-87. 2001
    ..Further therapies may target cytokine receptors on AML blasts, to improve anti-leukaemia therapy...
  39. ncbi More cell death in refractory anemia with excess blasts in transformation than in acute myeloid leukemia
    Y O Huh
    Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston 77030, USA
    Leukemia 16:2249-52. 2002
    ..The data suggest that RAEB-T is more likely to be an advanced stage of MDS and biologically different from AML...
  40. ncbi CECA-cyclophosphamide, etoposide, carboplatin and cytosine arabinoside--a new salvage regimen for relapsed or refractory acute myelogenous leukemia
    S M Kornblau
    Section of Molecular Hematology and Therapy, The University of Texas M D Anderson Cancer Center, Houston, USA
    Leuk Lymphoma 28:371-5. 1998
    ..The CECA regimen should be investigated in better prognosis salvage groups...
  41. ncbi High expression of the receptor tyrosine kinase Tie-1 in acute myeloid leukemia and myelodysplastic syndrome
    S Verstovsek
    Department of Leukemia, University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, Texas 77030, USA
    Leuk Lymphoma 42:511-6. 2001
    ..The role of Tie-1 overexpression in the reported increased vascularity in the bone marrow of AML and MDS patients requires further investigation...
  42. ncbi Quantitative single cell determination of ERK phosphorylation and regulation in relapsed and refractory primary acute myeloid leukemia
    M R Ricciardi
    Department of Blood Transplantation, Section of Molecular Hematology and Therapy, The University of Texas, MD Anderson Cancer Center, Houston, TX 77030, USA
    Leukemia 19:1543-9. 2005
    ..The ability of ERK inhibition to promote growth arrest rather than apoptosis suggests that clinical trials of MEK/ERK inhibitors may be more effective when combined with chemotherapy...
  43. ncbi Plasma hepatocyte growth factor is a prognostic factor in patients with acute myeloid leukemia but not in patients with myelodysplastic syndrome
    S Verstovsek
    Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston 77030, USA
    Leukemia 15:1165-70. 2001
    ..No significant correlation was observed between HGF levels and complete remission rate or duration. In the multivariate analysis HGF retained its significance as prognostic factor in AML (P = 0.02), along with age (P = 0.0005)...
  44. ncbi Cyclophosphamide, ara-C and topotecan (CAT) for patients with refractory or relapsed acute leukemia
    J Cortes
    Department of Leukemia, The University of Texas, M D Anderson Cancer Center, Houston 77030, USA
    Leuk Lymphoma 36:479-84. 2000
    ..In summary, the CAT regimen is well tolerated and has significant anti-leukemia activity which warrants further investigation...
  45. ncbi Risk factors of myelodysplastic syndromes: a case-control study
    S S Strom
    Department of Epidemiology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Leukemia 19:1912-8. 2005
    ..22). Results from this large study suggest that several factors play a role in MDS predisposition with possible joint effects. Risk profiles seem to differ by FAB type and gender...
  46. ncbi New drugs for therapy of AML
    E H Estey
    University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Leukemia 16:306-9. 2002
  47. ncbi Reducing mortality associated with immediate treatment complications of adult leukemias
    E Estey
    Department of Leukemia, The University of Texas M.D. Anderson Cancer Center, Houston, TX 77030, USA
    Semin Hematol 38:32-7. 2001
    ..D. Anderson are examining the role of intravenous itraconazole, which produces higher concentrations than itraconazole capsules in prophylaxis, and the role of FK 463 in treatment of fungal infections...
  48. ncbi Topotecan and cytarabine is an active combination regimen in myelodysplastic syndromes and chronic myelomonocytic leukemia
    M Beran
    Departments of Leukemia and Molecular Hematology, and Division of Laboratory Medicine, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    J Clin Oncol 17:2819-30. 1999
    ..To evaluate the efficacy and safety of the combination of topotecan and cytarabine in patients with myelodysplastic syndromes (MDSs) and chronic myelomonocytic leukemia (CMML)...
  49. ncbi The prognostic impact of BCL2 protein expression in acute myelogenous leukemia varies with cytogenetics
    S M Kornblau
    Department of Molecular Hematology and Therapy, The University of Texas M D Anderson Cancer Center, Houston 77030 4095, USA
    Clin Cancer Res 5:1758-66. 1999
    ....
  50. ncbi Clinical and laboratory studies of 2-chlorodeoxyadenosine +/- cytosine arabinoside for relapsed or refractory acute myelogenous leukemia in adults
    S M Kornblau
    Department of Hematology, University of Texas MD Anderson Cancer Center, Houston 77030, USA
    Leukemia 10:1563-9. 1996
    ..While combination of Ara-C with 2CdA increases the Ara-CTP uptake in these heavily treated patients this regimen does not appear to be an improvement over existing modalities...
  51. ncbi Pharmacologically directed design of leukemia therapy
    W Plunkett
    Department of Medical Oncology, University of Texas MD Anderson Cancer Center, Houston
    Haematol Blood Transfus 33:610-3. 1990
    ..An understanding of the cellular pharmacodynamics of other drugs is likely to be a useful parameter for planning treatment protocols...
  52. ncbi Phase I study of mitoxantrone plus etoposide with multidrug blockade by SDZ PSC-833 in relapsed or refractory acute myelogenous leukemia
    S M Kornblau
    Section of Molecular Hematology and Therapy, University of Texas M D Anderson Cancer Center, Houston 77030, USA
    J Clin Oncol 15:1796-802. 1997
    ..A phase I study using the nonimmunosuppressive MDR1 blocker SDZ PSC-833 (PSC) in combination with mitoxantrone (MITO) and etoposide (VP) was performed...
  53. ncbi Chlorodeoxyadenosine and arabinosylcytosine in patients with acute myelogenous leukemia: pharmacokinetic, pharmacodynamic, and molecular interactions
    V Gandhi
    Department of Clinical Investigation, University of Texas M D Anderson Cancer Center, Houston 77030, USA
    Blood 87:256-64. 1996
    ....
  54. ncbi Biochemical modulation of arabinosylcytosine for therapy of leukemias
    V Gandhi
    Department of Medical Oncology, University of Texas M D Anderson Cancer Center, Houston 77030
    Leuk Lymphoma 10:109-14. 1993
    ..These studies demonstrate that protocols designed on biochemical and pharmacological rationales modulate ara-C metabolism during therapies...
  55. ncbi Patient-specific dose rate for continuous infusion high-dose cytarabine in relapsed acute myelogenous leukemia
    V Heinemann
    Department of Medical Oncology, University of Texas, M D Anderson Cancer Center, Houston 77030
    J Clin Oncol 7:622-8. 1989
    ..This opens the possibility that pharmacologic determinations may be used to redirect the ara-C dose rate to achieve a desired ara-CTPss level in leukemia blasts during therapy...
  56. ncbi Low and maximally phosphorylated levels of the retinoblastoma protein confer poor prognosis in newly diagnosed acute myelogenous leukemia: a prospective study
    S M Kornblau
    Department of Molecular Hematology and Therapy, The University of Texas M D Anderson Cancer Center, Houston 77030 4095, USA
    Clin Cancer Res 4:1955-63. 1998
    ..Therefore, therapeutic decisions based on the level of RB expression may be indicated, and protocols to incorporate this are currently under development...
  57. ncbi Pharmacological and biochemical strategies to increase the accumulation of arabinofuranosylguanine triphosphatein primary human leukemia cells
    C O Rodriguez
    Departments of Clinical Investigation and Hematology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Cancer Res 3:2107-13. 1997
    ..Extension of these studies to ex vivo incubations confirmed our in vitro findings. These strategies will be used in the design of clinical protocols to increase ara-GTP accumulation in leukemia cells during therapy...
  58. ncbi High-dose cytosine arabinoside in chronic lymphocytic leukemia: a clinical and pharmacologic analysis
    L E Robertson
    Department of Hematology, University of Texas, M D Anderson Cancer Center, Houston 77030
    Leuk Lymphoma 10:43-8. 1993
    ..We conclude that high-dose ara-C has modest activity in CLL and that its use in combination with other agents in the treatment of CLL is warranted...
  59. ncbi Comparison of amphotericin B lipid complex (ABLC) vs. ambisome in the treatment of suspected or documented fungal infections in patients with leukemia
    R V Fleming
    Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston 77030, USA
    Leuk Lymphoma 40:511-20. 2001
    ..AmBisome was better tolerated than ABLC but was associated with mild abnormalities in liver function tests at the end of therapy...
  60. ncbi Accumulation of arabinosyluracil 5'-triphosphate during arabinosylcytosine therapy in circulating blasts of patients with acute myelogenous leukemia
    V Gandhi
    Department of Clinical Investigation, The University of Texas M D Anderson Cancer Center, Houston 77030, USA
    Clin Cancer Res 4:1719-26. 1998
    ..The present study demonstrated that circulating leukemia blasts accumulate ara-UTP during in vitro incubations with ara-C and during ara-C therapy...
  61. pmc Therapeutic targeting of the MEK/MAPK signal transduction module in acute myeloid leukemia
    M Milella
    Department of Blood and Marrow Transplantation, Section of Molecular Hematology and Therapy, The University of Texas, M.D. Anderson Cancer Center, Houston, Texas 77030, USA
    J Clin Invest 108:851-9. 2001
    ..Interruption of constitutive MEK/MAPK signaling therefore represents a promising therapeutic strategy in AML...
  62. doi The prognostic significance of serum beta2 microglobulin levels in acute myeloid leukemia and prognostic scores predicting survival: analysis of 1,180 patients
    Apostolia Maria Tsimberidou
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Cancer Res 14:721-30. 2008
    ..Serum beta(2) microglobulin (beta2M) is prognostic in other hematologic malignancies; therefore, we evaluated its prognostic significance in acute myeloid leukemia (AML)...
  63. ncbi Some ethical issues in phase II trials in acute leukemia
    Peter F Thall
    Department of Biostatistics and Applied Mathematics, University of Texas M D Anderson Cancer Center, Houston 77030, USA
    Clin Adv Hematol Oncol 3:943-8. 2005
    ..The general conclusions are that statistical designs have both scientific and ethical implications, and that science, statistics, and ethics cannot be treated as separate issues...
  64. ncbi Adaptive randomized study of idarubicin and cytarabine versus troxacitabine and cytarabine versus troxacitabine and idarubicin in untreated patients 50 years or older with adverse karyotype acute myeloid leukemia
    Francis J Giles
    Department of Leukemia, Box 428, University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
    J Clin Oncol 21:1722-7. 2003
    ..A prospective, randomized study was conducted in patients aged 50 years or older with untreated, adverse karyotype, acute myeloid leukemia (AML) to assess troxacitabine-based regimes as induction therapy...
  65. ncbi Some ethical issues in phase II trials in acute leukemia
    Peter F Thall
    Clin Adv Hematol Oncol 4:95. 2006
  66. pmc Simultaneous activation of multiple signal transduction pathways confers poor prognosis in acute myelogenous leukemia
    Steven M Kornblau
    Section of Molecular Hematology and Therapy, Unit 448, University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
    Blood 108:2358-65. 2006
    ..It is thus likely that only combinations of agents that target the multiply activated STPs will be beneficial for patients with AML...
  67. ncbi The clinical spectrum of adult acute myeloid leukaemia associated with core binding factor translocations
    Frederick R Appelbaum
    Southwest Oncology Group Statistical Center, Seattle, WA, USA
    Br J Haematol 135:165-73. 2006
    ..021), and in patients with t(8;21) (P = 0.025). OS was superior in patients who received regimens with high-dose cytarabine, a combination of fludarabine and intermediate-dose cytarabine, or haematopoietic cell transplantation...
  68. ncbi Adaptive dose selection using efficacy-toxicity trade-offs: illustrations and practical considerations
    Peter F Thall
    Department of Biostatistics and Applied Mathematics, The University of Texas, MD Anderson Cancer Center, Houston, USA
    J Biopharm Stat 16:623-38. 2006
    ..To illustrate how the method may work in practice, we present a cohort-by-cohort example of a particular trial. We close with a discussion of some practical issues that may arise during implementation...
  69. ncbi Randomized phase I/II study of troxacitabine combined with cytarabine, idarubicin, or topotecan in patients with refractory myeloid leukemias
    Francis J Giles
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    J Clin Oncol 21:1050-6. 2003
    ..Troxacitabine has significant single-agent activity. This study was conducted to define the dose-limiting toxicities (DLTs) of its combination with cytarabine (ara-C), idarubicin, or topotecan...
  70. ncbi Contribution of beta-2 microglobulin levels to the prognostic stratification of survival in patients with myelodysplastic syndrome (MDS)
    Simona Gatto
    M D Anderson Cancer Center, 1515 Holcombe Blvd, Box 428, Houston, TX 77030, USA
    Blood 102:1622-5. 2003
    ..While the results must be verified in an independent and comparable population, our data strongly recommend routine measurement of B2M in patients with MDS...
  71. ncbi Gemtuzumab ozogamicin with or without interleukin 11 in patients 65 years of age or older with untreated acute myeloid leukemia and high-risk myelodysplastic syndrome: comparison with idarubicin plus continuous-infusion, high-dose cytosine arabinoside
    Elihu H Estey
    Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Blood 99:4343-9. 2002
    ..Thus, there is little evidence to suggest that GO with or without IL-11 should be used instead of IA in older patients with newly diagnosed AML or myelodysplastic syndrome...
  72. ncbi Combination therapy with arsenic trioxide, all-trans retinoic acid, and gemtuzumab ozogamicin in recurrent acute promyelocytic leukemia
    Ahmed Aribi
    Department of Leukemia, University of Texas M D Anderson Cancer Center, Houston, Texas, USA
    Cancer 109:1355-9. 2007
    ..Arsenic trioxide (ATO) is an effective agent for the salvage of patients with recurrent APL, and gemtuzumab ozogamicin (GO) has shown activity in patients with APL...
  73. ncbi Myelodysplastic syndrome is not merely "preleukemia"
    Maher Albitar
    Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston 77030 4095, USA
    Blood 100:791-8. 2002
    ....
  74. ncbi Advances in the management of AML in the elderly
    Elihu H Estey
    Department of Leukemia, University of Texas M D Anderson Cancer Center, Houston, TX, USA
    Clin Adv Hematol Oncol 5:185-7. 2007
  75. doi Older adults: should the paradigm shift from standard therapy?
    Elihu H Estey
    Section of Acute Leukemia and Myelodysplastic Syndrome, Division of Cancer Medicine, MD Anderson Cancer Center, Box 428, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Best Pract Res Clin Haematol 21:61-6. 2008
    ..Nonetheless, these older patients are not uniform and can be stratified to receive investigational therapy, which is mandatory for most, or standard therapy, which is not inappropriate for some...
  76. ncbi Safety and clinical activity of the combination of 5-azacytidine, valproic acid, and all-trans retinoic acid in acute myeloid leukemia and myelodysplastic syndrome
    Andres O Soriano
    Department of Leukemia, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Blood 110:2302-8. 2007
    ..VPA blood levels were higher in responders (P < .005). In conclusion, the combination studied is safe and has significant clinical activity. This clinical trial was registered at www.clinicaltrials.gov as no. NCT00326170...
  77. doi Epidemiology of myelodysplastic syndromes
    Sara S Strom
    Department of Epidemiology, University of Texas MD Anderson Cancer Center, Houston, TX 77230, USA
    Semin Hematol 45:8-13. 2008
    ..Much still needs to be learned about what causes MDS and the genetic factors that increase susceptibility. Multi-institutional studies with a molecular-epidemiologic approach are necessary to develop a MDS risk predictive model...
  78. doi Phase I study of alternate-week administration of tipifarnib in patients with myelodysplastic syndrome
    Razelle Kurzrock
    Phase I Program, University of Texas MD Anderson Cancer Center, Houston, TX 77230 1402, USA
    Clin Cancer Res 14:509-14. 2008
    ..To determine the safety and describe the antitumor activity of tipifarnib in patients with myelodysplastic syndrome (MDS) using an alternate-week schedule...
  79. pmc Open-label, randomized comparison of itraconazole versus caspofungin for prophylaxis in patients with hematologic malignancies
    Gloria N Mattiuzzi
    Department of Leukemia, Unit 428, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Houston, Texas 77030, USA
    Antimicrob Agents Chemother 50:143-7. 2006
    ..In conclusion, intravenous itraconazole and caspofungin provided similar protection against invasive fungal infection during induction chemotherapy, and both drugs were well tolerated...
  80. ncbi Comparative efficacy and safety of gemtuzumab ozogamicin monotherapy and high-dose cytarabine combination therapy in patients with acute myeloid leukemia in first relapse
    Lance H Leopold
    Clinical Development and Medical Affairs in Oncology, GlaxcoSmithKline, Collegeville, PA 19426 0989, USA
    Clin Adv Hematol Oncol 1:220-5. 2003
    ..These data support the recommended use of gemtuzumab ozogamicin as monotherapy in older patients with AML in first relapse, but caution against this use in patients, particularly younger ones, with a long duration of CR1...
  81. ncbi Treatment of acute myelogenous leukemia
    Elihu H Estey
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, Texas, USA
    Oncology (Williston Park) 16:343-52, 355-6; discussion 357, 362, 365-6. 2002
    ..The evolution of new therapies for acute promyelocytic leukemia also is discussed, and the article provides a perspective on the changing role of hematopoietic stem cell transplantation for treatment of AML...
  82. ncbi Accounting for patient heterogeneity in phase II clinical trials
    J Kyle Wathen
    Department of Biostatistics, University of Texas, M D Anderson Cancer Center, Box 447, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Stat Med 27:2802-15. 2008
    ..A simulation study is presented and the method is illustrated by a chemotherapy trial in acute leukemia...
  83. ncbi Soluble vascular endothelial growth factor receptor 1, and not receptor 2, is an independent prognostic factor in acute myeloid leukemia and myelodysplastic syndromes
    Qinglong Hu
    Department of Hematopathology, The University of Texas M D Anderson Cancer Center, Houston, Texas, USA
    Cancer 100:1884-91. 2004
    ..Vascular endothelial growth factor (VEGF) and its receptors (VEGFRs) are major regulators of angiogenesis, which plays a key role in the growth and dissemination of solid tumors and hematologic neoplasms...
  84. ncbi Plasma vascular endothelial growth factor levels have prognostic significance in patients with acute myeloid leukemia but not in patients with myelodysplastic syndromes
    Alvaro Aguayo
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston 77030, USA
    Cancer 95:1923-30. 2002
    ..Increased levels in urine, serum, plasma, or malignant tissue have been associated with an adverse prognosis in patients with solid tumors...
  85. ncbi Intravenous corticosteroids to reduce gemtuzumab ozogamicin infusion reactions
    Francis J Giles
    Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX 77030 4009, USA
    Ann Pharmacother 37:1182-5. 2003
    ..To assess whether the addition of a brief course of intravenous corticosteroids reduces the incidence of infusion-related adverse events associated with gemtuzumab ozogamicin (GO) administration...
  86. ncbi Modulation of angiogenesis in patients with myelodysplastic syndrome
    Elihu H Estey
    Section of Acute Leukemia and Myelodysplastic Syndrome, Division of Cancer Medicine, MD Anderson Cancer Center, Box 428, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Best Pract Res Clin Haematol 17:623-39. 2004
    ....
  87. ncbi Independent prognostic significance of day 21 cytogenetic findings in newly-diagnosed acute myeloid leukemia or refractory anemia with excess blasts
    Marina Konopleva
    Department of Blood and Marrow Transplantation, Section of Molecular Hematology and Therapy, The University of Texas M D Anderson Cancer Center, Houston, Texas, USA
    Haematologica 88:733-6. 2003
    ..We investigated whether cytogenetic findings (CG) on day 21 (D21) of the first course of chemotherapy predicted subsequent outcome in patients who presented with CG abnormalities...
  88. ncbi Reduced-intensity conditioning for unrelated donor hematopoietic stem cell transplantation as treatment for myeloid malignancies in patients older than 55 years
    Raymond Wong
    Department of Blood and Marrow Transplantation, M D Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
    Blood 102:3052-9. 2003
    ..Unrelated donor transplantation is a treatment option for older patients with myeloid malignancies. The results in this cohort of patients are comparable with those reported in younger patients with similarly advanced disease...
  89. ncbi PML-RARalpha is associated with leptin-receptor induction: the role of mesenchymal stem cell-derived adipocytes in APL cell survival
    Yoko Tabe
    Department of Blood and Marrow Transplantation, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Blood 103:1815-22. 2004
    ..This report provides a mechanistic basis for the BM adipocyte-leukemia cell interaction and suggests that OB-R receptor blockade may have therapeutic use in APL...
  90. ncbi Phase II study of R115777, a farnesyl transferase inhibitor, in myelodysplastic syndrome
    Razelle Kurzrock
    Department of Bioimmunotherapy, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    J Clin Oncol 22:1287-92. 2004
    ....
  91. ncbi Prolonged infusion of gemcitabine: clinical and pharmacodynamic studies during a phase I trial in relapsed acute myelogenous leukemia
    Varsha Gandhi
    Department of Experimental Therapeutics, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    J Clin Oncol 20:665-73. 2002
    ..To determine the maximum tolerated duration of infusions at the fixed gemcitabine dose rate of 10 mg/m(2)/min and to analyze the pharmacodynamic actions in leukemia blasts during gemcitabine therapy...
  92. ncbi Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33-positive acute myeloid leukemia in first recurrence
    Richard A Larson
    Department of Medicine, University of Chicago, Chicago, Illinois, USA
    Cancer 104:1442-52. 2005
    ..In this study, the authors analyzed the efficacy and safety of gemtuzumab ozogamicin (GO) (Mylotarg), an antibody-targeted chemotherapy for CD33-positive acute myeloid leukemia (AML)...
  93. ncbi "3+7" therapy for the treatment of acute myeloid leukemia. CON
    Elihu H Estey
    University of Texas M D Anderson Cancer Center, USA
    Clin Adv Hematol Oncol 3:129-132, 141. 2005
  94. ncbi Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia
    Bruce D Cheson
    Department of Hematology Oncology, Georgetown University, Lombardi Cancer Center, 3800 Reservoir Rd, NW, Washington, DC 20007, USA
    J Clin Oncol 21:4642-9. 2003
    ..Storage of viable blasts for correlative studies is important for future progress in the therapy of these disorders...
  95. ncbi Association of cancer-related symptoms with physiological parameters
    Christina A Meyers
    J Pain Symptom Manage 24:359-61. 2002
  96. ncbi The clinical significance of soluble CD86 levels in patients with acute myeloid leukemia and myelodysplastic syndrome
    Barry D Hock
    Haematology Research Group, Christchurch Hospital, Christchurch, New Zealand
    Cancer 98:1681-8. 2003
    ..Levels of the soluble form of CD86 (sCD86) are elevated in a proportion of patients with leukemia. Although it is a potential modulator of antitumor responses, the significance of sCD86 in patients with hematologic malignancies is unknown...
  97. ncbi Increased apoptosis in bone marrow B lymphocytes but not T lymphocytes in myelodysplastic syndrome
    Hesham M Amin
    Department of Hematopathology, Box 72, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
    Blood 102:1866-8. 2003
    ..Our findings suggest that the alterations in B lymphocytes in the form of increased apoptosis can be seen in MDS and support the concept that immune modulation plays a role in the pathophysiology of MDS...
  98. ncbi Expression of CD2 in acute promyelocytic leukemia correlates with short form of PML-RARalpha transcripts and poorer prognosis
    Pei Lin
    Department of Hematopathology, The University of Texas M D Anderson Cancer Center, Houston 77030, USA
    Am J Clin Pathol 121:402-7. 2004
    ..07) than CD2- APL. Overall survival for M3v vs M3 (P = .68) and short vs long transcripts (P = .21) was not significantly different. Immunophenotyping is useful for predicting the biologic and clinical behavior of APL...
  99. ncbi Building and validating a prognostic index for biomarker studies
    Xuelin Huang
    Department of Biostatistics and Applied Mathematics, The University of Texas, M D Anderson Cancer Center, Houston, TX 77030, USA
    Cancer Biomark 2:97-101. 2006
    ..The prognostic index gets its power from combining prognostic biomarkers. It can be very powerful even when there are few markers that are predictive...
  100. ncbi Acquired PTPN11 mutations occur rarely in adult patients with myelodysplastic syndromes and chronic myelomonocytic leukemia
    Mignon L Loh
    Department of Pediatrics, University of California, San Francisco, CA, USA
    Leuk Res 29:459-62. 2005
    ..Here, we investigated contribution of PTPN11 mutations to adult MDS and CMML pathogenesis. Our results indicate that PTPN11 lesions might play a role in adult MDS/CMML pathogenesis but do not represent a major molecular event...
  101. ncbi CD34+ cell selection is required to assess HOXA9 expression levels in patients with myelodysplastic syndrome
    Stefan Heinrichs
    Department of Pediatric Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Br J Haematol 130:83-6. 2005
    ..These results indicate that CD34(+) cell selection is required to accurately assess the expression levels of HOXA9 and related genes in the multipotential malignant progenitor cells of MDS patients...